Search Results

You are looking at 151 - 160 of 182 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Rachel L. Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, and Lydia Usha

-agent carboplatin, tamoxifen, and anastrozole. Because the patient had a personal history of fallopian tube carcinoma, she was a candidate for genetic testing for BRCA1 and BRCA2 mutations. Additionally, due to a family history significant for multiple

Full access

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen

. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer . Lancet 2005 ; 365 : 60 – 62 . 21. Chlebowski RT Geller ML . Adherence to endocrine therapy for

Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel

For example, experts have suggested that the increased risk for endometrial cancer observed in some BRCA1 or 2 mutation carriers is mainly caused by the use of tamoxifen therapy rather than the presence of a gene mutation. 51 Germline mutations

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes

receptor–positive breast cancer to receive lumpectomy and tamoxifen with whole-breast RT or lumpectomy and tamoxifen for 5 years, no differences were seen in overall survival or breast cancer–specific survival. 249 , 250 However, locoregional recurrence

Full access

Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Bruce Compas, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Paul B. Jacobsen, Sara J. Knight, Kate Learson, Michael H. Levy, Matthew J. Loscalzo, Sharon Manne, Randi McAllister-Black, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, and Michael A. Zevon

possible mechanisms. 21 Nonadherence to treatment occurs, especially with oral medications. In women with primary breast cancer, Partridge et al. 22 observed that the overall adherence to tamoxifen decreased to 50% in the fourth year of therapy, and that

Full access

Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Luke O. Buchmann, Bruce Compas, Teresa L. Deshields, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Charles Hoover, Paul B. Jacobsen, Elizabeth Kvale, Michael H. Levy, Matthew J. Loscalzo, Randi McAllister-Black, Karen Y. Mechanic, Oxana Palesh, Janice P. Pazar, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, Michael A. Zevon, Nicole R. McMillian, and Deborah A. Freedman-Cass

to tamoxifen decreased to 50% in the fourth year of therapy and nearly one-fourth of patients may be at risk of inadequate clinical response because of poor adherence. In a meta-analysis, DiMatteo et al 17 found that non-compliance was 3 times

Full access

Hanna K. Sanoff, YunKyung Chang, Joseph M. Stavas, Til Stürmer, and Jennifer Lund

phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402) . Eur J Cancer 2008 ; 44 : 528 – 538

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

not make sense, particularly when the patient may require symptom-driven imaging studies for 20 years after completion of 5 years of tamoxifen. Depending on treatment and geographic location, our study found that 18% to 46% of patients received high

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

treatment consisted of tamoxifen or aromatase inhibitor according to hormonal receptor status and menopausal status. Statistical Analyses Statistical analyses were performed with SPSS Statistics for Windows, Version 19.0 (IBM Corp, Armonk, NY

Full access

Mary Ann Morgan and Crystal S. Denlinger

Miller K Merry B Miller J . Seasons of survivorship revisited . Cancer J 2008 ; 14 : 369 – 374 . 7 Davies C Pan H Godwin J . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of